RICO CONSPIRACY DOCUMENTS - COMMERCIALIZED ACCIDENTAL RELEASE

BACKGROUND; COMMERCIALIZED ACCIDENTAL RELEASE

According to an employee of Porton Down (presumably Susan O'Connell) when confronted by a member of the UK House of Lords over whether or not Porton Down and the CDC were still working with Borrelia as a bioweapon, the employee at first tried to deny that they were experimenting with Borrelia as a bioweapon (see what happened in Korea and China during the Korean War).  The UK Lord said, 'nonsense, don't lie to me about that,' essentially, and again asked the Porton Down employee if they were still studying Lyme as a bioweapon.  The Porton Down employee then admitted that the accidental release "was given over to industry."  Soon thereafter, Susan O'Connell either quit or was fired by the UK NHS (end of March, 2012).

We knew this anyway, and all along said, "We do not care if Lyme was an accidental release, but we do not need to be the victims of the RETards who handled it afterwards, who clearly did not know the first thing about Borrelia, relapsing fever and especially its surface antigens, as revealed by Crazy Eddie McSweegan in his 1986 letter to Senator Goldwater, when he speaks about 'cloned ehrlichial ligands' which is code language for Lyme vaccines.  These special Eddies did not know enough basic science to even see if other vaccines of the same type had been tried before and what the outcome was (Tuberculosis TLR2-agonist failed vaccines)."

You will see in the following documents and on 120702.htm both the bioweapons evidence and the RETARDED scientists (Susan O'Connell's "industry") who conspired to sell a vaccine that they knew did not prevent Lyme and for the basic capital investment (royalties and a monopoly on the national blood to pharm patentable goodies from all our blood, not just vector borne diseases data, but genetic bioweapons susceptibility data) for their stated enterprise, the ALDF.com

This is a snippet of an advertisement that was on Corixa.com's website where we see Corixa/Yale/Imugen being awarded an NIH biodefense contract for lying about the outcome of LYMErix. Corixa was later purchased by SmithKline, so all that 11.5 million dollars worth of USA biodefense data is now owned by a foreign company:
http://www.actionlyme.org/CORIXA_NIH_BIODEFENCE.pdf

More about this at the bottom of this page.  Scroll down for a lot more...
 

REPORTS YOU WILL NEED TO SHOW CONSPIRACY TO DEFRAUD Americans, Dumb Europeans, Russia, the Chinese...

 

Go to MedLine and enter borrelia and host-adapted:
http://www.ncbi.nlm.nih.gov/pubmed?term=%28%22borrelia%22%5BMeSH%20Terms%5D%20OR%20%22borrelia%22%5BAll%20Fields%5D%29%20AND%20host-adapted%5BAll%20Fields%5D&cmd=DetailsSearch

Those are all the people who know Lyme is simply a Relapsing Fever organism, that vaccines won't work, and that the  Dearborn case definition is research fraud. 

Host-adapted means the spirochete won't be expressing the same antigens it did when it was fresh out of a tick, due to antigenic variation.

 

 

DEARBORN AND EARLIER

Steere's original 1986 Lyme-diagnostic serology report:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC423723/?tool=pubmed

The above was mentioned at the 2001, Jan, FDA Meeting on LYMErix Adverse Events by Kathleen Dickson:
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2.htm

1990 CDC Serology standard (same as Steere's 1986 report; means Lyme is Relapsing Fever):
http://www.actionlyme.org/CDC_STANDARD_1990.htm

Dearborn Invitations (connotes consensus, which it was not):
http://www.actionlyme.org/DEARBORNINVITATIONS.pdf

Dearborn booklet (111 pages) showing no one agreed with Steere's proposal and who was on all the committees
http://www.actionlyme.org/DEARBORN_PDF.pdf

Gary Wormser's peer-reviewed assessment of Steere's Dearborn proposal where he says only 9/59 patients met the Steere/Dearborn  criteria for IgG (85% of cases are missed):
http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=266355&blobtype=pdf

"Steere in Europe" (the other report missing from Dearborn booklet which shows the research fraud where OspA and B are left out  http://www.actionlyme.org/STEERE_IN_EUROPE.htm (look at the ELISA cutoffs, this is clearly fraud)

“The group 1 strain of B. burgdorferi, G39/40, used in this study and in the previous study of US patients was isolated from an Ixodes damini tick in Guilford, Connecticut [21].  The group 2 strain, FRG [Federal Republic of Germany], was isolated from Ixodes ricinus near  Cologne [22].  The group 3 strain, IP3, was isolated from Ixodes persulcatus near Leningrad [23].  All three strains used in this study were high passage isolates, which were classified by Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT) using 16S ribosomal RNA sequence [revealing that he knows the OspA gene is the shell game] determination as described [11, 24].  The recombinant preparations of OspA and OspB used in this study were purified maltose- binding protein-Osp fusion proteins derived from group 1 strain B31 [25].  The fusion proteins contained the full-length OspA or OspB sequence without the lipid moiety or the signal sequence -" [OspA and B (encoded on the same plasmid) will not be seen in antibody-response without the lipids attached to the Osps.  This was how OspA and B were left out of the Dearborn panel - pure research fraud.]

 

CDC staff (Barbara Johnson) patents (5 of them) from 1992 in Europe with SmithKline explaining that there are 2 kinds of Lyme, the HLA-linked and the non-HLA linked, meaning the same characters who were there at the Dearborn conference, knew the outcome was scientific fraud and that it served their own patent interests for Lyme to be the fake disease it is now (high antibody concentration).  There can be no vaccines or antibody tests other than flagellin for Relapsing Fever
http://www.wikipatents.com/CA-Patent-2135800/compositions-useful-in-diagnosis-and-prophylaxis-of-lyme-disease

CDC's (Barbara Johnson) final serology standard (No OspA and B, which are encoded on the same plasmid)
http://wonder.cdc.gov/wonder/prevguid/m0038469/m0038469.asp

CDC's Barbara Johnson was present at Dearborn and approved a standard she knew was false and she did so to suit her own "patents in Europe with SmithKline" bottom line:
http://www.actionlyme.org/Dearborn_Who_Approved.htm
http://www.actionlyme.org/CDCS_PARTICIPATION_IN_LYME_CRIMES.htm

CDC Crooks say in their 5 European patents with SmithKline: "Certain of these antigens are characterized as being B. burgdorferi B31 strain specific and major histocompatibility complex (MHC) nonrestricted [these would be all the cases that are not "Bad-Knees-Only']. Certain other of these antigens are characterized as being MHC restricted [these would be all the cases of Dearborn-Positive-Bad-Knees-Only]...." 

 

CONCLUSION:  Lyme used to be considered Relapsing Fever and this was independently observed by Allen Steere, who said in 1986 that one only needed band 41 (flagellin) to be diagnosed with Lyme.  The CDC then sent Steere on a junket to Europe to narrow the disease definition the same year CDC staff (the other CDC officers - not Steere because he's not too bright) claimed patents with SmithKline in the European patent database.  Those patents identify two kinds of Lyme:  Steere's HLA-linked "bad-knees" and the other, Great Imitator, seronegative outcomes.  We find that fungal antigens carried by borrelia - like OspA - are themselves responsible for the Great Imitator outcomes in that they appear to inhibit apoptosis in EBV-infected cells, and tolerize to fungal infections in the blood, which contribute to fatigue.  Paralyzing fatigue is characteristic of late, chronic, neurologic Lyme.



 

WHO DID WHAT ONCE OspA and B WERE DROPPED FROM THE STANDARD

Persing and Schoen's RICO strain (dropped OspA and B, but was determined to be burgdorferi via the DNA/RNS shell game) report:
http://jcm.asm.org/cgi/reprint/35/1/233?view=long&pmid=8968914

Persing and Schoen's RICO strain and monopoly patent on post-LYMErix blood patent:
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
"Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure....

"The present invention provides a method useful to detect a B. burgdorferi infection in a subject. The method provided by the invention is particularly useful to discriminate B. burgdorferi infection from OspA vaccination, although it is sufficiently sensitive and specific to use in any general Lyme disease screening or diagnostic application. Thus, the method of the invention is particularly appropriate for large scale screening [THE MONOPOLY- this has implications for the current situation where this cabal now contracted with the Red Cross for a do-over of the same fraud-monopoly crime; they are interested only in patentable goodies in the blood while lying about everything else] or diagnostic applications where only part of the subject population has been vaccinated or where the vaccination status of the population is unknown. "

Evidence that Corixa, Imugen and L2 Diagnostics were officially SEC "partners"
https://groups.google.com/forum/?hl=en&fromgroups#!topic/sci.med.diseases.lyme/D6v-QHQdMbc

Evidence that Corixa did the advertising for the Corix-Imugen-L2 Diagnostics ("partners") cabal
https://groups.google.com/forum/?hl=en&fromgroups#!topic/sci.med.diseases.lyme/cy9beTF_Uqs

Evidence that the Yale Endowment Fund funded the former Yale Lyme and Lupus clinic, "L2 Diagnostics"
http://www.actionlyme.org/LYME_CORRUPTICUT.htm

Proof that Corixa's newest model of adjuvant was NOT tri-lipidated. Persing's company, Corixa, advertising selling a new form of OspA-adjuvant, monophosphoryl A, which is meant to be a mono-acyl version of OspA-the adjuvant, but not so toxic as OspA.
http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm

CONCLUSION:  We speculate that Steere is involved with Imugen financially, and his payoff for putting his name on the Dressler/Steere falsified serology reports was an official partnership with Corixa and Steere's pal Robert Schoen at L2-Diagnostics, Yale's former Lyme and Lupus Clinic.  Corixa, Imugen and L2 Diagnostics intended a monopoly on all blood in the United States because in it would be new vector-borne diseases' DNA to patent, and it also holds bioweapons value (HLA-differences among peoples) as you can see from the activities of the Russian scientists who publish in association with the ALDF.com cabal at New York Medical College, Valhalla, NY:
http://www.actionlyme.org/BOGUS_RUSSIAN_NYMC_ARTICLES.htm

 

THE SCIENTIFICALLY VALID ANTIBODY TEST FOR RELAPSING FEVER

Fikrig and Flavell's scientifically valid antibody test for B burgdorferi Relapsing Fever:
http://iai.asm.org/content/59/10/3531.full.pdf+html?view=long&pmid=1894359

Fikrig and Flavell's scientifically valid antibody test patent (5,618,533)
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5618533.PN.&OS=PN/5618533&RS=PN/5618533

Fikrig and Flavell's LYMErix OspA patent
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294

See the PowerPoint Presentation here to see where Yale and the CT Dept of Agriculture spiked the
Borrelia mix with extra flagellin to detect cases of Lyme where the antibody concentration is LOW - one of the goals
and attributes of a scientifically valid method (FDA rules): 
http://www.actionlyme.org/CRYMEDISEASE_CHP1.htm

The species determinant = Flagellin, See the Taxonomy database:
http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&id=138&lvl=3&lin=f&keep=1&srchmode=1&unlock
 

Dattwyler talking about the incurability of Spirochetal Diseases in 1988:

http://www.actionlyme.org/DODD_KENNEDY.htm (know what goes on on Plum Island)
 

YALE AND ALAN BARBOUR SAY THERE CAN BE NO Osp-BASED VACCINES AGAINST RELAPSING FEVER

Fikrig and Flavell's report where they show LYMErix would not work because Lyme is Relapsing Fever ("selection pressure")
http://www.actionlyme.org/SELECTION_PRESSURE_NO_VACCINE_POSSIBLE.htm
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC173206/pdf/631658.pdf|

Alan Barbour in 1992 reported that OspA, too, undergoes antigenic variation and therefore could not have been a vaccine
http://www.actionlyme.org/BARBOUR_MUTANTS_1992.htm

Alan Barbour discussing antigenic variation in general and what that means re diagnostics and vaccines (can't):
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627965/?tool=pubmed

Andrew Pachner (formerly at Yale) Discussing...:  
http://www.actionlyme.org/PACHNER_BRAINS_1990.htm

"The plasmid content of N40Br was different from that of the infecting strain implying either a highly selective process during infection or DNA rearrangement in the organism in vivo. "

Discussing antigenic variation; meaning, you can't Western Blot someone with late Lyme with a tick fresh out of a tick, due to antigenic variation or what the crooks call host-adaptation.  This means Dearborn is moot, and especially Klempner.

 

CONCLUSION: Fikrig and Flavell own the patents to Fla-burgdorferi and LYMErix OspA, and Barbour owns the patent for the ImmuLyme OspA vaccine, yet here they are saying the very idea is nonsense. Neither advised to stop the vaccine trials which were underway by 1993.  Lyme is Relapsing Fever.

 

THE YALE, CORIXA, IMUGEN CABAL KNEW LYMErix (OspA) CAUSED A CHRONIC-LYME-LIKE ILLNESS

Yale's Robert Schoen says in 1998 not to test LYMErix victims and minimizes their symptoms knowing chronic Lyme is identical to what Schoen says is "nonspecific" because the exact reverse statement is in the Corixa-RICO patent "multisystem complaints characteristic of late Lyme",  This is that textbook:
http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584/ref=sr_1_fkmr0_2?ie=UTF8&qid=1341914626&sr=8-2-fkmr0&keywords=lyme+disease+rhan+and+evans

http://www.actionlyme.org/SCHOEN_INSTRUCTING_DOCS_TO_BLOW_OFF_LYMERIX_INJUREES.htm

 

 

Dave Persing discussing why you should not use the native or original Osps as vaccines (and Robert Schoen would know this too):
http://www.actionlyme.org/STEALTH_DISABLERS.htm
"Accordingly, the methods of the invention provide a powerful and selective approach for modulating the innate immune response pathways in animals without giving rise to the toxicities often associated with the native bacterial components that normally stimulate those pathways."  
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/PTO/srchnum.htm&r=1&f=G&l=50&s1=6,800,613.PN.&OS=PN/6,800,613&RS=PN/6,800,613
http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm

Persing and Schoen's RICO strain and monopoly on post-LYMErix blood patent
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
"Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure....


SmithKline bought Corixa to keep all that OspA-failure-and-harm data proprietary

Munchausen's accusations against people they clearly knew were sick (1998) in this book:
http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584/ref=sr_1_fkmr0_2?ie=UTF8&qid=1341914626&sr=8-2-fkmr0&keywords=lyme+disease+rhan+and+evans

http://www.actionlyme.org/MUNCHAUSENS.htm

http://www.alibris.com/search/books/qwork/4078360/used/Lyme%20Disease This is the book the following is published in:

On the previous page of this Munchausen's book:

Steere says "seronegative Lyme is a conflict in terms when talking about arthritis" meaning that since the Dearborn conference, "Lyme Disease" officially became the arthritis, only (in the Munchausen's/Schoen lies book here>>
http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584/ref=sr_1_fkmr0_2?ie=UTF8&qid=1341914626&sr=8-2-fkmr0&keywords=lyme+disease+rhan+and+evans



Seronegative Lyme disease is a subtle, attenuated illness.  He means "low antibody concentration" - see the Western Blots
in the RICO complaint to see the difference:  http://www.actionlyme.org/USDOJ_COMPLAINT_RICO.htm 

IDSA Reviews, Special Supplement on Spirochetal Diseases (you have to look at all of them)
http://www.actionlyme.org/CHP_9_IDSA_REVIEWS.htm

Paul Duray twice reports that chronic Lyme victims have mutated B cells (1989, 1992 = Schutzer's book)
http://www.actionlyme.org/IDSA_CLINIPATH_DURAY.htm
http://www.actionlyme.org/Duray.htm

Dattwyler and Luft report that one has to look for new IgM bands (the old standard) in order to diagnose Lyme
(1992, Schutzer's book)



Trinity Biotech bought MarDx (Jeremy Gray is in Dublin; Gray is criminal partners with Susan O'Connell at Porton Down/ UK's NHS)  to keep all the OspA vaccines trial data (unreadable blots) out of the United States.

Dave Persing and Lenny Sigal report that the Western Blots of OspA vaccinated people assessed with MarDx were unreadable (blot smudging is due to the fact that the OspA molecules were not micellized enough by the carrier; people were injected with blobs of various sized lipids, resulting in all the strokes associated with the Phase III vaccine trial
http://www.journals.uchicago.edu/doi/pdf/10.1086/313920

Robert Schoen reports in the Phase VI LYMErix trial that tons of people died or were made sick or got cancer (OspA helps activate Epstein-Barr), and this would be because OspA sticks to itself, as also reported by the Koreans when they reported that the HIV gp120 antigen is the same thing as LYMErix (triacyl lipopeptide).
http://www.actionlyme.org/OspA_IV.htm
Korean Pam3Cys = HIVgp120 PDF
 

These are the essentials to demonstrate fraud over the testing and that the intention of it was to falsify the vaccines outcomes and changed the definition of the disease to "arthritis" or hypersensitivity, alone, and as shown in the RICO complaint to the USDOJ http://www.actionlyme.org/USDOJ_COMPLAINT_RICO.htm

Look at the blots in the RICO complaint.  This crime is so obvious....